Growth arrest associated changes of mRNA levels in breast cancer cells measured by semi-quantitative RT-PCR: potential early indicators of treatment response-Reference-Cited by-同舟云学术

Growth arrest associated changes of mRNA levels in breast cancer cells measured by semi-quantitative RT-PCR: potential early indicators of treatment response

Published:1995-10 Issue:1 Volume:97 Page:107-116
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Maas Riks A.,Bruning Peter F.,Top Bert,Breedijk Annette J.,Peterse Hans L.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference37 articles.

1. Endocrine therapy of breast cancer;Harmsen;Eur. J. Cancer Clin. Oncol.,1993

2. Drug resistance to tamoxifen during breast cancer therapy;Wolf;Breast Cancer Res. Treatment,1993

3. Expression of a set of growth related immediate early genes in Balbc 3T3 cells coordinate regulation with c-fos or c-myc;Lau,1987

4. Signals and genes in the control of cell-cycle progression;Müller;Biochim. Biophys. Acta,1993

5. Direct effects of estrogen on c-fos and c-myc protooncogene expression and cellular proliferation in human breast cancer cells;van der Burg;Mol. Cell. Endocrinol.,1989

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Organophosphate flame retardants induce oxidative stress and Chop/Caspase 3-related apoptosis via Sod1/p53/Map3k6/Fkbp5 in NCI-1975 cells;Science of The Total Environment;2022-05

2. Identification of MAGEA antigens as causal players in the development of tamoxifen-resistant breast cancer;Oncogene;2014-03-24

3. Graphene as a Nanocarrier for Tamoxifen Induces Apoptosis in Transformed Cancer Cell Lines of Different Origins;Small;2011-11-18

4. Tamoxifen citrate loaded biodegradable poly(sebacic acid-co- ricinoleic acid) microparticles, in vitro characterization;Journal of Drug Delivery Science and Technology;2011

5. The Efficacy of Tamoxifen in Estrogen Receptor–Positive Breast Cancer Cells Is Enhanced by a Medical Nutriment;Cancer Biotherapy and Radiopharmaceuticals;2004-12